ECL at a glance
Ecolab (ECL, SEC CIK 31462) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ecolab (ECL) reported revenue of $16.1 billion (up 2.2% from FY2024) and net income of $2.1 billion. Diluted EPS was $7.28.
- As of September 30, 2026, 53 institutional investment managers tracked by SignalX reported holding Ecolab (ECL) shares worth $31.1 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by MacLennan David on November 12, 2026 of 600 shares at $308.13 per share.
- In the last 90 days, ECL insiders reported 3 open-market purchases ($1.2M) and 0 open-market sales ($0) on Form 4, a net purchase of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $16.1B
- +2.2% vs prior year
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$1.2M
- 13F holders
- 53 funds
- $31.1B · −1 vs prior quarter
- Latest 8-K
- Nov 17, 2026
- Item 2.05
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- ~47% of net sales from outside U.S. with exposure to tariffs, retaliatory trade measures, and currency risk in 170+ countries
- $8.2B total debt outstanding, ~$1.5B floating rate; 1pp rate increase adds ~$15M annual interest expense
- U.S. Gulf Coast concentration risk: key raw material source and customer base for Light & Heavy segment, vulnerable to hurricanes and severe weather
- OECD Pillar Two 15% global minimum tax now effective in multiple jurisdictions; OBBBA interaction creates complex compliance and double-taxation risk
- AI and ERP upgrade execution risk: ongoing multi-phase ERP rollout plus "One Ecolab" restructuring; failure could cause business disruption and financial losses
Management Discussion & Analysis
- Revenue $16.1B, up 2% YoY ($339.8M increase); organic sales +3%, driven by pricing and volume across all segments
- Reported operating margin 17.0% vs 17.8% in 2024; adjusted operating margin 18.0% vs 16.6%, boosted by value pricing and productivity
- Best segment: Global Institutional & Specialty, organic operating margin 22.8% vs 19.9%; worst: Global Life Sciences, smallest at $706M sales despite margin recovery to 17.1% vs 13.7%
- Operating cash flow $3.0B vs $2.8B; capex $1.0B; share buybacks $784M; dividends paid $754M; Ovivo Electronics acquired for $1.6B cash
- One Ecolab restructuring expanded Feb 2026 to $334M total cost targeting $325M annualized savings by 2027; FX exposure and geopolitical risk (Russia/Ukraine ~1% of sales) cited as key risks
Business Overview
- Global leader in water, hygiene and infection prevention; $16B annual sales, 48,000 associates, 170+ countries, 40 industries
- Four reportable segments this filing: Global Water, Global Institutional & Specialty, Global Pest Elimination, Global Life Sciences; Life Sciences explicitly elevated as standalone segment
- Warewashing products grew to 13% of consolidated net sales in 2025, up from 12% in 2024 and 2023: only product line disclosed at 10%+ threshold
- Capital expenditures for environmental, health and safety projects held steady at ~$62M in 2025 (vs $46M in 2023), with $59M budgeted for 2026
- Workforce of ~25,000 in sales/service roles plus ~3,000 R&D/digital experts; 43% North America, notable 8% India/Middle East/Africa concentration disclosed
AI summary of the ECL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes reported from the December 31, 2025 Form 10-K risk factors
- Carried-forward risk: factors could materially reduce future financial performance
- Forward-looking statement risk: actual results may differ materially from expectations
- Disclosure risk: oral presentations and public webcasts may contain forward-looking statements
Management Discussion & Analysis
- Revenue $4,694.8M, up 13% YoY from $4,165.0M
- Reported operating margin 17.3% vs 18.3% YoY, organic margin 19.6% vs 18.9%
- Best segment: Global Life Sciences organic sales up 17% to $215.8M, margin 23.3% vs 18.3%
- Worst segment: Global Pest Elimination organic margin 20.8% vs 20.9%, down 0.1 percentage points
- Cash $722.3M, operating cash flow $1,939.1M, acquisitions and affiliate investments $4.7B through nine months
- Outlook: strong operating cash flow expected, with commodity and logistics cost pressures from geopolitics and energy volatility
AI summary of the ECL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.05: Costs Associated with Exit or Disposal Activities
- One Ecolab restructuring expanded, targeting global centers of excellence and digital-enabled functional realignment
- Total restructuring costs $485 million, including $378 million after tax, expected by end of 2030
Item 2.02: Results of Operations and Financial Condition
- Ecolab announced third-quarter 2026 earnings for the period ended September 30, 2026
- News release and supplemental data available in Exhibits 99.1 and 99.2
Item EX-99.1: Item EX-99.1
- Q3 sales $4.695B, up 13%, with organic growth accelerating to 7%, signaling broad-based demand and pricing strength
- Adjusted EPS $2.18, up 5%, despite an approximate 10% CoolIT-related amortization and financing headwind
Item EX-99.2: Item EX-99.2
- 3Q 2026 sales $4.695B, up 13%, with organic growth accelerating to 7% on 2% volume and 5% pricing
- Adjusted EPS $2.18, up 5%, despite an approximate 10-point CoolIT amortization and financing headwind
Item EX-99.1: Item EX-99.1
- Q2 sales $4.4B, up 10%, with organic growth accelerating to 5%; pricing reached 4% despite Middle East disruptions
- Adjusted diluted EPS $2.09, up 11%, while reported EPS rose 3% to $1.90; productivity offset commodity inflation
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 earnings announced for quarter ended June 30, 2026
- News release furnished as Exhibit 99.1, containing the detailed financial results
Item EX-99.2: Item EX-99.2
- Q2 2026 sales $4.42B, up 10%; organic growth accelerated to 5%, led by Life Sciences, Pest Elimination and High-Tech
- Adjusted diluted EPS $2.09, up 11%; organic operating margin expanded 40 bps to 18.8%
AI summaries of ECL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ECL
Don't miss the next ECL filing
- Alerts as it files. A push when ECL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ECL, by share count.
- Ask anything. An AI agent that reads every ECL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MacLennan David | Buy | Nov 12, 2026 | 600 | $308.13 |
| Boone Jandeen M | F | Nov 2, 2026 | 654.242 | $306.35 |
| Mewhorter Bryce L | M | Nov 2, 2026 | 2,948 | - |
| Clark Benjamin M. | M | Nov 2, 2026 | 8,843 | - |
| Clark Benjamin M. | M | Nov 2, 2026 | 8,843 | - |
| Boone Jandeen M | M | Nov 2, 2026 | 1,769 | - |
| Mewhorter Bryce L | M | Nov 2, 2026 | 2,948 | - |
| Mewhorter Bryce L | F | Nov 2, 2026 | 1,344.289 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $15.7B | $16.1B |
| Operating Income | $2.0B | $2.8B | $2.7B |
| Net Income | $1.4B | $2.1B | $2.1B |
| Op. Margin | - | 17.8% | 17.0% |
| Net Margin | - | 13.4% | 12.9% |
| Balance Sheet | |||
| Total Assets | - | $22.4B | $24.7B |
| Equity | - | $8.8B | $9.8B |
| ROE | - | 24.1% | 21.2% |
| Per Share | |||
| EPS | - | $7.37 | $7.28 |
| Cash Flow | |||
| Operating CF | $2.4B | $2.8B | $3.0B |
| CapEx | $774.8M | $994.5M | $1.0B |
Source: XBRL data in Ecolab (ECL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ECL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 53 | $31.11B |
| Q2 2026 | 54 | $30.49B |
| Q1 2026 | 58 | $28.21B |
| Q4 2025 | 54 | $27.68B |
| Q3 2025 | 56 | $30.69B |
| Q2 2025 | 54 | $27.11B |
| Q1 2025 | 51 | $19.37B |
| Q4 2024 | 47 | $14.70B |
- Bank of America Corp+3.41M (+164%)
- JPMorgan Chase & Co+2.18M (+15%)
- Vanguard Portfolio Management LLC+198.0K (+3%)
- Wells Fargo & Co+176.8K (+11%)
- Dimensional Fund Advisors+166.0K (+14%)
- BlackRock−493.8K (-2%)
- Morgan Stanley−334.2K (-4%)
- Northern Trust−122.5K (-4%)
- Millennium Management−85.8K (-50%)
- U.S. Bancorp−76.8K (-7%)
- StoneX Group Inc.+2.0K
- FMR LLC (Fidelity)−1.53M
- Equitable Holdings Inc−9.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 427 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ECL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 17, 2026 | - | Analysis | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
Related Materials companies
- AEM · Agnico Eagle Mines LtdGold and Silver Ores
- APD · Air ProductsIndustrial Inorganic Chemicals
- ALB · Albemarle CorporationPlastic Materials, Synth Resins & Nonvulcan Elastomers
- AA · Alcoa CorpPrimary Production of Aluminum
- AMCR · AmcorMiscellaneous Manufacturing Industries
- ABAT · AMERICAN BATTERY TECHNOLOGY CoMining & Quarrying of Nonmetallic Minerals (No Fuels)
- AMWD · AMERICAN WOODMARK CORPMillwood, Veneer, Plywood, & Structural Wood Members
- APOG · APOGEE ENTERPRISES, INC.Glass Products, Made of Purchased Glass
ECL SEC filings: frequently asked questions
Are ECL insiders buying or selling?
In the last 90 days, Ecolab (ECL) officers, directors and 10% owners reported 3 open-market purchases worth $1.2 million by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ECL stock?
As of September 30, 2026, the largest Ecolab (ECL) holders among the 13F filers tracked by SignalX were BlackRock ($6.2 billion), JPMorgan Chase & Co ($4.7 billion), Vanguard Capital Management LLC ($4.5 billion), State Street Corp ($3.2 billion), Morgan Stanley ($2.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ECL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ecolab (ECL) reported revenue of $16.1 billion (up 2.2% from FY2024) and net income of $2.1 billion. Diluted EPS was $7.28. The figures come from the XBRL data in the 10-K.
What are the main risks in ECL's latest 10-K?
In the 10-K filed February 23, 2026, Ecolab (ECL) flagged: ~47% of net sales from outside U.S. with exposure to tariffs, retaliatory trade measures, and currency risk in 170+ countries. $8.2B total debt outstanding, ~$1.5B floating rate; 1pp rate increase adds ~$15M annual interest expense. (AI summary of the Risk Factors section.)
What did ECL report in its latest 8-K?
Ecolab (ECL) filed an 8-K on November 17, 2026 reporting Item 2.05 (Costs Associated with Exit or Disposal Activities). One Ecolab restructuring expanded, targeting global centers of excellence and digital-enabled functional realignment.
What are the latest ECL SEC filings?
Ecolab (ECL) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on November 12, 2026.
What is ECL's SEC CIK number?
Ecolab (ECL)'s SEC Central Index Key (CIK) is 31462. EDGAR lists every ECL filing under that number.
Ask anything about ECL
The research agent reads ECL's filings, financials, insider trades and 13F holders, then answers with sources.